Bridgeway Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bridgeway Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-159,000	Closed	-$176K	–	1448
2022 Q4	$176K	Sell	159,000 -5,000	-3%	-$7.12K	﹤0.01%	1114
2022 Q3	$384K	Buy	+164,000	New	+$581K	0.01%	964
2020 Q3	–	Sell	-31,300	Closed	-$216K	–	1375
2020 Q2	$216K	Sell	31,300 -294,200	-90%	-$1.59M	﹤0.01%	1135
2020 Q1	$1.55M	Buy	325,500 +99,600	+44%	+$573K	0.04%	428
2019 Q4	$1.97M	Buy	225,900 +72,300	+47%	+$391K	0.03%	563
2019 Q3	$511K	Sell	153,600 -94,300	-38%	-$377K	0.01%	953
2019 Q2	$1.23M	Buy	247,900 +20,800	+9%	+$110K	0.02%	669
2019 Q1	$1.41M	Sell	227,100 -71,200	-24%	-$344K	0.02%	645
2018 Q4	$1M	Buy	298,300 +95,000	+47%	+$444K	0.01%	728
2018 Q3	$1.32M	Buy	+203,300	New	+$1.51M	0.01%	767

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Bridgeway Capital Management's JNCE Position: Q1 2023 in Review

Bridgeway Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 159,000 shares — an estimated $176K sold.

Bridgeway Capital Management first reported a position in JNCE in Q3 2018 and held it in 10 quarters. The position peaked at $1.97M in Q4 2019. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

Bridgeway Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Bridgeway Capital Management sold 159,000 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $176K.
Bridgeway Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
Bridgeway Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $1.97M in Q4 2019.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.